# BBV152/BBV154 Heterologus Prime-Boost Study

> **NCT05639998** · PHASE2 · COMPLETED · sponsor: **Bharat Biotech International Limited** · enrollment: 608 (actual)

## Conditions studied

- Corona Virus Infection

## Interventions

- **BIOLOGICAL:** COVAXIN(BBV152)
- **BIOLOGICAL:** BBV154 Intranasal Vaccine

## Key facts

- **NCT ID:** NCT05639998
- **Lead sponsor:** Bharat Biotech International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-07-31
- **Target enrollment:** 608 (ACTUAL)
- **Last updated:** 2022-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05639998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05639998, "BBV152/BBV154 Heterologus Prime-Boost Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05639998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*